Retatrutide triple hormone receptor agonist for obesity

Retatrutide triple hormone receptor agonist for obesity

New England Journal of Medicine

2023

Study summary

Retatrutide investigated as GLP-1/GIP/glucagon receptor agonist for obesity treatment.

Peptides studied

Stack studied

Advanced Metabolic Stack

Key findings

Marked reductions in body weight were reported in phase 2 trials.

Study details

Study type

phase 2 clinical trial

Journal

New England Journal of Medicine

DOI / PubMed

10.1056/NEJMoa2301972

Year

2023

Explore peptide profiles

Discover compounds, understand their mechanisms, and explore the research behind each peptide.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.

Explore the science. Follow the connections.

Start with a peptide, a goal, a mechanism, or a study. Discover how every piece of research connects across the platform.

Search peptides, goals, studies,...

Research made connected. Build for curious minds.

© 2026 All rights reserved

This platform is for informational and research purposes only. It does not provide medical advice. Always consult a qualified healthcare provider.